Ann: Opthea to Present at SVB Leerink Healthcare Conference, page-12

Key points from webcast Q&A:
• Moderator asked whether OPT-302 could be co-formulated with Lucentis and/or Eylea (i.e. one injection). CEO said that OPT were very interested in co-formulating, noting that existing drugs are coming off patent in the next 12 months. Also noted that they don’t expect any roadblocks to co-formulating, i.e. there’s nothing in the chemistry of OPT-302 vs Lucentis/Eylea that suggests you would have issues
• Considering running a separate arm of the phase 3 trial to test ‘durability’, i.e frequency of injections. Compliance with anti-VEGF treatment programs isn’t great, so pushing out the frequency is a major focus for new drugs. CEO noted that this would be a nice to have, but the main game is the increased efficacy of OPT-302 combination treatment over existing drugs
• On partnering v financing independently, CEO noted that they’re well set up to move forward independently, but there are a lot of benefits to partnering. Didn’t commit either way
• On timing of finalizing capital requirements and potential partners, confirmed this would occur this year before they get too deep into phase 3